Slowly Does It: The EMA’s Approach To Expanding Multinational Drug Assessment Concept
Executive Summary
The European Medicines Agency’s multinational approach to drug assessment under which new marketing authorization applications are evaluated by teams formed according to expertise rather than by country has proved popular and is now being expanded to the “complex” post-authorization phase. The multinational assessment team (MNAT) concept will be broadened in phases, starting in April. Issues relating to sustainability, knowledge transfer and payment of fees to participating national authorities all have to be considered.
You may also be interested in...
The Tricky Task Of Bringing Smaller EU Countries Into The Fold
Clusters of excellence, competition as well as co-operation, Brexit, and aiming high. Danish Medicines Agency head Thomas Senderovitz talks national agencies and engagement in an interview with the Pink Sheet.
EMA Multinational Assessment Teams Move Into Post-Authorization After Delay
The scope of the European Medicines Agency’s multinational assessment team initiative was originally due to expand in April from the pre-authorization to the post-authorization phase. It will happen next month instead.
EMA’s Multinational Approach Brings All But Two Member States Into New Drug Assessor Fold
The multinational assessment team (MNAT) approach aimed to involve more EU member states in the evaluation of new medicines. EMA views it as a success, although only about 10% of marketing authorization applications submitted for initial evaluation in 2015 involved MNATs. It will shortly be expanded to certain post-authorization procedures and is being promoted as a tool that will help the agency deal with Brexit fallout.